下一代補體療法的全球市場:按目標疾病/適應症(非典型溶血性尿毒症綜合徵、心臟移植排斥反應、冷凝集素病、COVID-19、系統性重症肌無力)
市場調查報告書
商品編碼
1063801

下一代補體療法的全球市場:按目標疾病/適應症(非典型溶血性尿毒症綜合徵、心臟移植排斥反應、冷凝集素病、COVID-19、系統性重症肌無力)

Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis,

出版日期: | 出版商: Roots Analysis | 英文 131 Slides | 商品交期: 最快1-2個工作天內

價格

自2007年抗C5抗體Soliris(R)獲批以來,補體藥物發現領域備受關注。目前,市場上有九種補體療法,約有190種分子正在開發中,旨在適應各種疾病。

本報告分析了下一代補體療法的全球市場,並提供了技術概述和功能、當前臨床試驗進展、基本市場結構和最新情況、主要公司概況和近期業務聯盟。/我們將為您提供合作/研究資助/資助趨勢、整體市場規模趨勢、細分/地區詳細趨勢以及主要上市/管道產品概述等資訊。

文字中的圖表示例

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章介紹

  • 補體系統概述
  • 參與補體系統的免疫細胞
  • 補體系統的特點
  • 補系統功能
  • 補體在體內平衡和壓力條件下的作用
  • 激活補體系統
  • 補體蛋白的主要來源
  • 補體蛋白經典途徑的功能
  • 補充系統路徑
    • 經典路線
    • 甘露糖結合凝集素
    • 替代路線
    • 最終路線
  • 補體系統失調的結果
  • 與補體蛋白缺陷相關的疾病
  • 補體療法的種類
  • 補體治療的局限性
  • 下一代補體療法的未來

第 4 章下一代補體療法:市場情況

  • 分析方法及主要參數
  • 下一代補體療法:開發管線
  • 下一代補體療法:特殊指定藥物清單
  • 下一代補體療法:開發公司的情況

第 5 章公司簡介

  • Amgen
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • CSL Behring
  • Innovent Biologics
  • Novartis
  • Regeneron
  • Roche
  • Sanofi
  • Takeda
  • UCB

第 6 章臨床試驗分析

  • 調查方法和關鍵指標
  • 下一代補體療法:臨床試驗列表

第 7 章出版物分析

  • 調查方法和關鍵指標
  • 下一代補體療法:出版物列表

第 8 章授權分析

  • 調查方法和關鍵指標

第 9 章專利分析

  • 調查方法和關鍵指標
  • 下一代補體療法:專利列表

第 10 章商業聯盟/合作

  • 下一代補體療法:商業聯盟與合作清單

第 11 章融資/投資分析

  • 下一代補充療法:融資/投資清單

第 12 章主要製藥公司

  • 調查方法和關鍵指標
  • 指標評分
  • 主要製藥公司:收入資訊(2021 年)

第 13 章市場規模和機會分析

  • 調查方法和關鍵指標
  • 全球下一代補體療法市場(2022-2035)
  • 已上市的下一代補體療法全球市場(2022-2035 年)
    • 按目標疾病/適應症(2022-2035)
    • 按分子類型 (2022-2035)
    • 按目標路線 (2022-2035)
    • 按治療類型 (2022-2035)
    • 按給藥途徑 (2022-2035)
  • 已上市產品的銷售預測
    • Berinert (CSL Behring)
    • EMPAVELI (Apellis Pharmaceuticals)
    • ORLADEYO (BioCryst Pharmaceuticals)
    • Ruconest(Pharming)
    • Solidis (Alexion Pharmaceuticals)
    • Takhzyro(Takeda)
    • Ultomiris (Alexion Pharmaceuticals)
  • 全球 III 期下一代補充療法市場(2022-2035 年)
    • 按目標疾病/適應症(2022-2035)
    • 按治療區域 (2022-2035)
    • 按目標路線 (2022-2035)
    • 按治療類型 (2022-2035)
    • 按給藥途徑 (2022-2035)
    • 按地區 (2022-2035)
  • 三期產品銷售預測
    • Narsoprimab (Omeros)
    • REGN3918 (Regeneron)
    • RG6107 (Ruconest)
    • rVA576 (Akari Therapeutics)
    • SAR445088(Sanofi)
    • Soliris (Alexion Pharmaceuticals)
    • Stimlimab (Bioverativ)
    • Viroberimab (InflaRx)
    • Zilucoplan (UCB)
  • 摘要:III期藥物

第 14 章專家意見

  • New York Oncology Hematology
    • 組織概覽
    • 專家意見
  • Cedars-Sinai Tower Hematology Oncology Medical
  • Weill Cornell Medical College
  • Leiden University Medical Center
  • Lund University

第 15 章附錄1:圖表列表

第 16 章附錄2:公司/組織名單

Title:
Next Generation Complement Therapeutics Market:
Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview:

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady growth over the coming years.

Scope of the Report:

The 'Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters.
  • Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
  • A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
  • An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
  • An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • An analysis of the partnerships that have been established in this domain since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
  • A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
  • An analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with next generation complement therapeutics market in the mid to long term. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035.

Our year wise projections of the current and forecasted opportunity within the next generation complement therapeutics market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?
  • What is the focus area of various publications related to the next generation complement therapeutics?
  • Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors, active in the field of next generation complement therapeutics?
  • What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?
  • How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the next generation complement therapeutics market in the mid to long term.

Chapter 3 provides a general overview of complement system including information on the immune cells involved in complement system, and sources of key complement proteins. In addition, the chapter presents details on the complement activation pathways (classical, lectin, alternative and terminal pathway). It also features information on consequences of a dysregulated complement system, types of complement therapeutics, limitations and future of next generation complement therapeutics.

Chapter 4 provides an overview of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous) and type of therapy (monotherapy and combination therapy).

Chapter 5 includes detailed profiles of key players engaged in the development of next generation complement therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 6 provides information on more than 870 completed, ongoing and planned clinical studies of next generation complement therapeutics, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), popular therapeutics area(s), type of drug, emerging focus areas and regional distribution of trials.

Chapter 7 features a detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular indication(s) and therapeutic area(s) (in terms of number of articles published).

Chapter 8 provides an in-depth analysis of grants that have been awarded to various research institutes for projects related to next generation complement therapeutics, during 2017-2021, on the basis of important parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section. The chapter also highlights type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.

Chapter 9 features an in-depth analysis of the patents that have been filed / granted for next generation complement therapeutics, between 2016-2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.

Chapter 10 features an analysis of the partnerships that have been established in this domain, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, research and development agreements and other relevant types of deals.

Chapter 11 presents detailed analysis of various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.

Chapter 12 includes an analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

Chapter 13 presents an insightful market forecast analysis, highlighting the future potential of the next generation complement therapeutics market till the year 2035. It includes future sales projections of next generation complement therapeutics that are either marketed or are likely to be marketed within the next two years. In order to provide a detailed future outlook, our projections have been segmented across (A) Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), (B) Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), (C) Type of Molecule (Biologics and Small Molecules), (D) Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), (E) Type of Therapy (Monotherapy and Combination Therapy), (F) Route of Administration (Intravenous, Oral and Subcutaneous), and (G) Key Geographical Regions (North America, Europe and Asia-Pacific).

Chapter 14 presents expert opinion in the complement therapeutics domain.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of Complement System
  • 3.2. Immune Cells Involved in Complement System
  • 3.3. Characteristics of Complement System
  • 3.4. Functions of Complement System
  • 3.5. Role of Complement in Homeostasis and Stress Conditions
  • 3.6. Activation of Complement System
    • 3.6.1. Steps in Complement Activation
  • 3.7. Sources of Key Complement Proteins
  • 3.8. Functions of Complement Proteins of Classical Pathway
  • 3.9. Pathways of Complement System
    • 3.9.1. Classical Pathway
    • 3.9.2. Lectin Pathway
    • 3.9.3. Alternative Pathway
    • 3.9.4. Terminal Pathway
  • 3.10. Consequences of a Dysregulated Complement System
  • 3.11. Diseases related to Defects in Complement Proteins
  • 3.12. Types of Complement Therapeutics
  • 3.13. Limitations of Complement Therapeutics
  • 3.14. Future of Next Generation Complement Therapeutics

4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE

  • 4.1. Analysis Methodology and Key Parameters
  • 4.2. Next Generation Complement Therapeutics: Development Pipeline
    • 4.2.1. Analysis by Status of Development
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Status of Development and Type of Molecule
    • 4.2.4. Analysis by Type of Drug
    • 4.2.5. Analysis by Biological Target
    • 4.2.6. Analysis by Target Pathway
    • 4.2.7. Analysis by Mechanism of Action
    • 4.2.8. Analysis by Mechanism of Action and Target Pathway
    • 4.2.9. Analysis by Target Disease Indication(s)
    • 4.2.10. Analysis by Status of Development and Target Disease Indication(s)
    • 4.2.11. Analysis by Therapeutic Area
    • 4.2.12. Analysis by Therapeutic Area and Type of Molecule
    • 4.2.13. Analysis by Route of Administration
    • 4.2.14. Analysis by Type of Therapy
    • 4.2.15. Analysis by Dosing Frequency
    • 4.2.16. Grid Analysis: Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
  • 4.3. Next Generation Complement Therapeutics: List of Drugs with Special Designations
    • 4.3.1. Analysis by Special Designation
  • 4.4. Next Generation Complement Therapeutics: Developer Landscape
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Region of Headquarters
    • 4.4.4. Analysis by Company Size and Region of Headquarters
    • 4.4.5. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES

  • 5.1. Amgen
    • 5.1.1. Company Overview
    • 5.1.2. Financial Information
    • 5.1.3. Product Portfolio
    • 5.1.4. Recent Developments and Future Outlook
  • 5.2. CSL Behring
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Product Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. Innovent Biologics
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Product Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Novartis
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Product Portfolio
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. Regeneron
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Product Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Roche
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Product Portfolio
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Sanofi
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Product Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Takeda
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Product Portfolio
    • 5.8.4. Recent Developments and Future Outlook
  • 5.9. UCB
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Product Portfolio
    • 5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Analysis Methodology and Key Parameters
  • 6.2. Next Generation Complement Therapeutics: List of Clinical Trials
    • 6.2.1. Analysis by Trial Status
    • 6.2.2. Cumulative Analysis by Trial Registration Year
    • 6.2.3. Analysis by Trial Registration Year and Status
    • 6.2.4. Analysis by Trial Phase
    • 6.2.5. Analysis by Trial Phase and Patients Enrolled
    • 6.2.6. Analysis by Trial Registration Year and Patients Enrolled
    • 6.2.7. Analysis by Type of Sponsor / Collaborator
    • 6.2.8. Analysis by Type of Study
    • 6.2.9. Analysis by Study Design
    • 6.2.10. Most Active Industry Players: Analysis by Number of Trials
    • 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
    • 6.2.12. Analysis by Disease Indication
    • 6.2.13. Most Popular Therapeutic Areas: Analysis by Number of Trials
    • 6.2.14. Analysis by Type of Treatment
    • 6.2.15. Analysis by Type of Drug
    • 6.2.16. Word Cloud Analysis: Emerging Focus Areas
    • 6.2.17. Analysis by Top Indications and Phase of the Trial
    • 6.2.18. Analysis by Top Indications and Leading Industry Players
    • 6.2.19. Analysis by Trial Location
    • 6.2.20. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS

  • 7.1. Analysis Methodology and Key Parameters
  • 7.2. Next Generation Complement Therapeutics: List of Publications
    • 7.2.1. Analysis by Year of Publication
    • 7.2.2. Word Cloud Analysis: Emerging Focus Areas
    • 7.2.3. Top Authors: Analysis by Number of Publications
    • 7.2.4. Key Journals based on Number of Publications
    • 7.2.5. Key Journals based on Impact Factor
    • 7.2.6. Popular Indications based on Number of Publications
    • 7.2.7. Popular Therapeutic Areas based on Number of Publications

8. GRANT ANALYSIS

  • 8.1. Analysis Methodology and Key Parameters
    • 8.1.1. Analysis by Year of Grants Awarded
    • 8.1.2. Analysis by Amount Awarded
    • 8.1.3. Analysis by Funding Institute Center
    • 8.1.4. Analysis by Support Period
    • 8.1.5. Analysis by Funding Institute Center and Support Period
    • 8.1.6. Analysis by Type of Grant
    • 8.1.7. Analysis by Activity Code
    • 8.1.8. Popular Recipient Organizations: Analysis by Number of Grants
    • 8.1.9. Popular Recipient Organizations: Analysis by Amount Awarded
    • 8.1.10. Popular NIH Departments: Analysis by Number of Grants
    • 8.1.11. Analysis by Study Section
    • 8.1.12. Analysis by Type of Recipient Organization
    • 8.1.13. Word Cloud Analysis: Emerging Focus Areas
    • 8.1.14. Analysis by Purpose of Grant
    • 8.1.15. Prominent Program Officers: Analysis by Number of Grants
    • 8.1.16. Analysis by Location of Recipient Organizations

9. PATENT ANALYSIS

  • 9.1. Analysis Methodology and Key Parameters
  • 9.2. Next Generation Complement Therapeutics: List of Patents
    • 9.2.1. Analysis by Patent Publication Year
    • 9.2.2. Analysis of Year-wise Granted Patents
    • 9.2.3. Analysis by Type of Patent
    • 9.2.4. Analysis by Granted Patents and Patent Applications
    • 9.2.5. Analysis by Geography
    • 9.2.6. Analysis by CPC Symbols
    • 9.2.7. Analysis by Type of Applicant
    • 9.2.8. Analysis of Patents by Age
    • 9.2.9. Word Cloud Analysis: Emerging Focus Areas
    • 9.2.10. Leading Industry Players: Analysis by Number of Patents
    • 9.2.11. Leading Non-Industry Players: Analysis by Number of Patents
    • 9.2.12. Leading Individual Assignees: Analysis by Number of Patents
    • 9.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
    • 9.2.14. Patent Valuation: Analysis Methodology and Parameters
    • 9.2.15. Patent Valuation: Analysis by Relative Valuation

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Next Generation Complement Therapeutics: List of Partnerships and Collaborations
    • 10.1.1. Analysis by Year-wise Trend of Partnership
    • 10.1.2. Analysis by Type of Partnership
    • 10.1.3. Analysis by Year and Type of Partnership
    • 10.1.4. Most Popular Drug: Analysis by Number of Partnerships
    • 10.1.5. Analysis by Biological Target
    • 10.1.6. Analysis by Target Pathway
    • 10.1.7. Word Cloud Analysis: Emerging Focus Areas
    • 10.1.8. Analysis by Drug and Type of Partnership
    • 10.1.9. Analysis by Type of Partner
    • 10.1.10. Analysis by Popular Disease Indication
    • 10.1.11. Analysis by Popular Disease Indication and Type of Partnership
    • 10.1.12. Analysis by Therapeutic Area
    • 10.1.13. Analysis by Therapeutic Area and Type of Partnership
    • 10.1.14. Regional Analysis of Partnerships
    • 10.1.15. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Next Generation Complement Therapeutics: List of Funding and Investments
    • 11.1.1. Cumulative Year-wise Trend
    • 11.1.2. Analysis by Amount Invested per Year
    • 11.1.3. Analysis by Type of Funding and Year of Establishment
    • 11.1.4. Analysis of Instances by Type of Funding
    • 11.1.5. Analysis of Amount Invested by Type of Funding
    • 11.1.6. Analysis by Year, Type of Funding and Amount Invested
    • 11.1.7. Most Active Investors: Analysis by Number of Instances
    • 11.1.8. Most Active Players: Analysis by Number of Funding Instances
    • 11.1.9. Most Active Players: Analysis by Amount Raised
    • 11.1.10. Analysis of Amount by Drug
    • 11.1.11. Analysis of Number of Instances by Drug
    • 11.1.12. Summary of Investments

12. BIG PHARMA PLAYERS

  • 12.1 Analysis Methodology and Key Parameters
  • 12.2. Scoring of Parameters
  • 12.3. Big Pharma Players: Information on Revenues Generated in 2021
    • 12.3.1. Analysis by Supplier Strength
    • 12.3.2. Analysis by Portfolio Strength
    • 12.3.3. Analysis by Portfolio Diversity
    • 12.3.4. Benchmarking: Spider Web Analysis
    • 12.3.5. Benchmarking: Harvey Ball Analysis
    • 12.3.6. Benchmarking: Wind Rose Chart

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Forecast Methodology and Key Parameters
  • 13.2. Global Next Generation Complement Therapeutics Market, 2022-2035
  • 13.3. Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035
    • 13.3.1. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Disease Indication
      • 13.3.1.1. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
      • 13.3.1.2. Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035
    • 13.3.2. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Molecule
      • 13.3.2.1. Next Generation Complement Therapeutics Market for Biologics, 2022-2035
      • 13.3.2.2. Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035
    • 13.3.3. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Pathway
      • 13.3.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
      • 13.3.3.2. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
      • 13.3.3.3. Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035
      • 13.3.3.4. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
    • 13.3.4. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Therapy
      • 13.3.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
      • 13.3.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
    • 13.3.5. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Route of Administration
      • 13.3.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
      • 13.3.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
      • 13.3.5.3. Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035
  • 13.4. Product-wise Sales Forecast for Marketed Drugs
    • 13.4.1. Berinert (CSL Behring)
      • 13.4.1.1. Sales Forecast (USD Billion)
    • 13.4.2. EMPAVELI (Apellis Pharmaceuticals)
      • 13.4.2.1. Sales Forecast (USD Billion)
    • 13.4.3. ORLADEYO (BioCryst Pharmaceuticals)
      • 13.4.3.1. Sales Forecast (USD Billion)
    • 13.4.4. Ruconest (Pharming)
      • 13.4.4.1. Sales Forecast (USD Billion)
    • 13.4.5. Soliris (Alexion Pharmaceuticals)
      • 13.4.5.1. Sales Forecast (USD Billion)
    • 13.4.6. Takhzyro (Takeda)
      • 13.4.6.1. Sales Forecast (USD Billion)
    • 13.4.7. Ultomiris (Alexion Pharmaceuticals)
      • 13.4.7.1. Sales Forecast (USD Billion)
  • 13.5. Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035
    • 13.5.1. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Disease Indication
      • 13.5.1.1. Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
      • 13.5.1.2. Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035
      • 13.5.1.3. Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035
      • 13.5.1.4. Next Generation Complement Therapeutics Market for COVID-19, 2022-2035
      • 13.5.1.5. Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035
      • 13.5.1.6. Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035
      • 13.5.1.7. Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035
      • 13.5.1.8. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
    • 13.5.2. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Therapeutic Area
      • 13.5.2.1. Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035
      • 13.5.2.2. Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035
      • 13.5.2.3. Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035
      • 13.5.2.4. Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035
      • 13.5.2.5. Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035
      • 13.5.2.6. Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035
    • 13.5.3. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Pathway
      • 13.5.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
      • 13.5.3.2. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
      • 13.5.3.3. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
    • 13.5.4. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Type of Therapy
      • 13.5.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
      • 13.5.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
    • 13.5.5. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Route of Administration
      • 13.5.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
      • 13.5.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
    • 13.5.6. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Geography
      • 13.5.6.1. Next Generation Complement Therapeutics Market in North America, 2022-2035
        • 13.5.6.1.1. Next Generation Complement Therapeutics Market in US, 2022-2035
        • 13.5.6.1.2. Next Generation Complement Therapeutics Market in Canada, 2022-2035
      • 13.5.6.2. Next Generation Complement Therapeutics Market in Europe, 2022-2035
        • 13.5.6.2.1. Next Generation Complement Therapeutics Market in UK, 2022-2035
        • 13.5.6.2.2. Next Generation Complement Therapeutics Market in Germany, 2022-2035
        • 13.5.6.2.3. Next Generation Complement Therapeutics Market in France, 2022-2035
        • 13.5.6.2.4. Next Generation Complement Therapeutics Market in Italy, 2022-2035
        • 13.5.6.2.5. Next Generation Complement Therapeutics Market in Spain, 2022-2035
      • 13.5.6.3. Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035
        • 13.5.6.3.1. Next Generation Complement Therapeutics Market in Australia, 2022-2035
        • 13.5.6.3.2. Next Generation Complement Therapeutics Market in Japan, 2022-2035
        • 13.5.6.3.3. Next Generation Complement Therapeutics Market in China, 2022-2035
        • 13.5.6.3.4. Next Generation Complement Therapeutics Market in India, 2022-2035
  • 13.6. Product-wise Sales Forecast for Phase III Drugs
    • 13.6.1. Narsoplimab (Omeros)
      • 13.6.1.1. Target Patient Population
      • 13.6.1.2. Sales Forecast (USD Billion)
      • 13.6.1.3. Net Present Value (USD Billion)
      • 13.6.1.4. Value Creation Analysis
    • 13.6.2. REGN3918 (Regeneron)
      • 13.6.2.1. Target Patient Population
      • 13.6.2.2. Sales Forecast (USD Billion)
      • 13.6.2.3. Net Present Value (USD Billion)
      • 13.6.2.4. Value Creation Analysis
    • 13.6.3. RG6107 (Ruconest)
      • 13.6.3.1. Target Patient Population
      • 13.6.3.2. Sales Forecast (USD Billion)
      • 13.6.3.3. Net Present Value (USD Billion)
      • 13.6.3.4. Value Creation Analysis
    • 13.6.4. rVA576 (Akari Therapeutics)
      • 13.6.4.1. Target Patient Population
      • 13.6.4.2. Sales Forecast (USD Billion)
      • 13.6.4.3. Net Present Value (USD Billion)
      • 13.6.4.4. Value Creation Analysis
    • 13.6.5. SAR445088 (Sanofi)
      • 13.6.5.1. Target Patient Population
      • 13.6.5.2. Sales Forecast (USD Billion)
      • 13.6.5.3. Net Present Value (USD Billion)
      • 13.6.5.4. Value Creation Analysis
    • 13.6.6. Soliris (Alexion Pharmaceuticals)
      • 13.6.6.1. Target Patient Population
      • 13.6.6.2. Sales Forecast (USD Billion)
      • 13.6.6.3. Net Present Value (USD Billion)
      • 13.6.6.4. Value Creation Analysis
    • 13.6.7. Sutimlimab (Bioverativ)
      • 13.6.7.1. Target Patient Population
      • 13.6.7.2. Sales Forecast (USD Billion)
      • 13.6.7.3. Net Present Value (USD Billion)
      • 13.6.7.4. Value Creation Analysis
    • 13.6.8. Vilobelimab (InflaRx)
      • 13.6.8.1. Target Patient Population
      • 13.6.8.2. Sales Forecast (USD Billion)
      • 13.6.8.3. Net Present Value (USD Billion)
      • 13.6.8.4. Value Creation Analysis
    • 13.6.9. Zilucoplan (UCB)
      • 13.6.9.1. Target Patient Population
      • 13.6.9.2. Sales Forecast (USD Billion)
      • 13.6.9.3. Net Present Value (USD Billion)
      • 13.6.9.4. Value Creation Analysis
  • 13.7. Summary: Phase III Drugs

14. EXPERT OPINION

  • 14.1. New York Oncology Hematology
    • 14.1.1. Overview of Organization
    • 14.1.2. Expert Opinion: Mihir Raval (Physician)
  • 14.2. Cedars-Sinai Tower Hematology Oncology Medical
    • 14.2.1. Overview of Organization
    • 14.2.2. Expert Opinion: Jeremy Lorber (Hematologist Oncologist)
  • 14.3. Weill Cornell Medical College
    • 14.3.1. Overview of Organization
    • 14.3.2. Expert Opinion: Jeffrey Conrad Laurence (Senior Scientific Consultant)
  • 14.4. Leiden University Medical Center
    • 14.4.1. Overview of Organization
    • 14.4.2. Expert Opinion: YKO (Onno) Teng (Nephrology Clinician-Scientist
  • 14.5. Lund University
    • 14.5.1. Overview of Organization
    • 14.5.2. Expert Opinion: Mårten Segelmark (Professor of Nephrology)

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Immune Cells Involved in Complement System
  • Figure 3.2 Role of Complement in Homeostasis and Stress Conditions
  • Figure 3.3 Activation of Complement System
  • Figure 3.4 Steps in Complement Activation
  • Figure 3.5 Pathways of Complement System
  • Figure 3.6 Consequences of a Dysregulated Complement System
  • Figure 3.7 Types of Complement Therapeutics
  • Figure 3.8 Limitations of Complement Therapeutics
  • Figure 3.9 Future of Next Generation Complement Therapeutics
  • Figure 4.1 Next Generation Complement Therapeutics: Distribution by Status of Development
  • Figure 4.2 Next Generation Complement Therapeutics: Distribution by Type of Molecule
  • Figure 4.3 Next Generation Complement Therapeutics: Distribution by Status of Development and Type of Molecule
  • Figure 4.4 Next Generation Complement Therapeutics: Distribution by Type of Drug
  • Figure 4.5 Next Generation Complement Therapeutics: Distribution by Biological Target
  • Figure 4.6 Next Generation Complement Therapeutics: Distribution by Target Pathway
  • Figure 4.7 Next Generation Complement Therapeutics: Distribution by Mechanism of Action
  • Figure 4.8 Next Generation Complement Therapeutics: Distribution by Mechanism of Action and Target Pathway
  • Figure 4.9 Next Generation Complement Therapeutics: Distribution by Target Disease Indication(s)
  • Figure 4.10 Next Generation Complement Therapeutics: Distribution by Status of Development and Target Disease Indication(s)
  • Figure 4.11 Next Generation Complement Therapeutics: Distribution by Therapeutic Area
  • Figure 4.12 Next Generation Complement Therapeutics: Distribution by Therapeutic Area and Type of Molecule
  • Figure 4.13 Next Generation Complement Therapeutics: Distribution by Route of Administration
  • Figure 4.14 Next Generation Complement Therapeutics: Distribution by Type of Therapy
  • Figure 4.15 Next Generation Complement Therapeutics: Distribution by Dosing Frequency
  • Figure 4.16 Grid Analysis: Distribution by Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
  • Figure 4.17 Next Generation Complement Therapeutics: Distribution by Special Designation
  • Figure 4.18 Next Generation Complement Therapeutics Developers: Distribution by Year of Establishment
  • Figure 4.19 Next Generation Complement Therapeutics Developers: Distribution by Company Size
  • Figure 4.20 Next Generation Complement Therapeutics Developers: Distribution by Region of Headquarters
  • Figure 4.21 Next Generation Complement Therapeutics Developers: Distribution by Company Size and Region of Headquarters
  • Figure 4.22 Leading Players: Distribution by Number of Therapeutics
  • Figure 5.1 Amgen: Financial Information
  • Figure 5.2 CSL Behring: Financial Information
  • Figure 5.3 Innovent Biologics: Financial Information
  • Figure 5.4 Novartis: Financial Information
  • Figure 5.5 Regeneron: Financial Information
  • Figure 5.6 Roche: Financial Information
  • Figure 5.7 Sanofi: Financial Information
  • Figure 5.8 Takeda: Financial Information
  • Figure 5.9 UCB: Financial Information
  • Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-2021)
  • Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Status, (Pre-2001-2021)
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.8 Clinical Trial Analysis: Distribution by Type of Study
  • Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
  • Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
  • Figure 6.12 Clinical Trial Analysis: Distribution by Disease Indication
  • Figure 6.13 Most Popular Therapeutic Areas: Distribution by Number of Trials
  • Figure 6.14 Clinical Trial Analysis: Distribution by Type of Treatment
  • Figure 6.15 Clinical Trial Analysis: Distribution by Type of Drug
  • Figure 6.16 Word Cloud Analysis: Emerging Focus Areas
  • Figure 6.17 Clinical Trial Analysis: Distribution by Top Indications and Phase of the Trial
  • Figure 6.18 Clinical Trial Analysis: Distribution by Top Indications and Leading Industry Players
  • Figure 6.19 Clinical Trial Analysis: Distribution by Trial Location
  • Figure 6.20 Clinical Trial Analysis: Distribution by Geography and Trial Status
  • Figure 7.1 Publication Analysis: Distribution by Year of Publication
  • Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
  • Figure 7.3 Top Authors: Distribution by Number of Publications
  • Figure 7.4 Key Journals: Distribution by Number of Publications
  • Figure 7.5 Key Journals: Distribution by Impact Factor
  • Figure 7.6 Popular Indications: Distribution by Number of Publications
  • Figure 7.7 Popular Therapeutic Areas: Distribution by Number of Publications
  • Figure 8.1 Grant Analysis: Distribution by Year of Grants Awarded
  • Figure 8.2 Grant Analysis: Distribution by Amount Awarded
  • Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
  • Figure 8.4 Grant Analysis: Distribution by Support Period
  • Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 8.6 Grant Analysis: Distribution by Type of Grant
  • Figure 8.7 Grant Analysis: Distribution by Activity Code
  • Figure 8.8 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 8.9 Popular Recipient Organizations: Distribution by Amount Awarded
  • Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
  • Figure 8.11 Grant Analysis: Distribution by Study Section
  • Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 8.13 Word Cloud Analysis: Emerging Focus Areas
  • Figure 8.14 Grants Analysis: Distribution by Purpose of Grant
  • Figure 8.15 Prominent Program Officers: Distribution by Number of Grants
  • Figure 8.16 Grant Analysis: Distribution by Location of Recipient Organizations
  • Figure 9.1 Patent Analysis: Distribution by Patent Publication Year
  • Figure 9.2 Patent Analysis: Year-wise Distribution of Granted Patents
  • Figure 9.3 Patent Analysis: Distribution by Type of Patent
  • Figure 9.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
  • Figure 9.5 Patent Analysis: Distribution by Geography
  • Figure 9.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 9.7 Patent Analysis: Distribution by Type of Applicant
  • Figure 9.8 Patent Analysis: Distribution of Patents by Age
  • Figure 9.9 Word Cloud Analysis: Emerging Focus Areas
  • Figure 9.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 9.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 9.12 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 9.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 9.14 Patent Valuation: Distribution by Relative Valuation
  • Figure 10.1 Partnerships and Collaborations: Distribution by Year-wise Trend of Partnership
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Most Popular Drug: Distribution by Number of Partnerships
  • Figure 10.5 Partnerships and Collaborations: Distribution by Biological Target
  • Figure 10.6 Partnerships and Collaborations: Distribution by Target Pathway
  • Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
  • Figure 10.8 Partnerships and Collaborations: Distribution by Drug and Type of Partnership
  • Figure 10.9 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.10 Partnerships and Collaborations: Distribution by Popular Disease Indication
  • Figure 10.11 Partnerships and Collaborations: Distribution by Popular Disease Indication and Type of Partnership
  • Figure 10.12 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 10.13 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
  • Figure 10.14 Regional Distribution of Partnerships
  • Figure 10.15 Intercontinental and Intracontinental Agreements
  • Figure 11.1 Funding and Investments: Cumulative Year-wise Trend
  • Figure 11.2 Funding and Investments: Distribution by Amount Invested per Year
  • Figure 11.3 Funding and Investments: Distribution by Type of Funding and Year of Establishment
  • Figure 11.4 Funding and Investments: Distribution of Instances by Type of Funding
  • Figure 11.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Figure 11.6 Funding and Investments: Distribution by Year, Type of Funding and Amount Invested
  • Figure 11.7 Most Active Investors: Distribution by Number of Instances
  • Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 11.9 Most Active Players: Distribution by Amount Raised
  • Figure 11.10 Funding and Investments: Distribution of Amount by Drug
  • Figure 11.11 Funding and Investments: Distribution of Number of Instances by Drug
  • Figure 11.12 Funding and Investments: Summary of Investments
  • Figure 12.1 Distribution by Supplier Strength
  • Figure 12.2 Distribution by Portfolio Strength
  • Figure 12.3 Distribution by Portfolio Diversity
  • Figure 12.4 Benchmarking: Spider Web Analysis
  • Figure 12.5 Benchmarking: Harvey Ball Analysis
  • Figure 12.6 Benchmarking: Wind Rose Chart
  • Figure 13.1 Global Next Generation Complement Therapeutics Market, 2022-2035 (USD Billion)
  • Figure 13.2 Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion)
  • Figure 13.3 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Target Disease Indication
  • Figure 13.4 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035 (USD Billion)
  • Figure 13.5 Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035 (USD Billion)
  • Figure 13.6 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Type of Molecule
  • Figure 13.7 Next Generation Complement Therapeutics Market for Biologics, 2022-2035 (USD Billion)
  • Figure 13.8 Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035 (USD Billion)
  • Figure 13.9 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Target Pathway
  • Figure 13.10 Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035 (USD Billion)
  • Figure 13.11 Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035 (USD Billion)
  • Figure 13.12 Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035 (USD Billion)
  • Figure 13.13 Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035 (USD Billion)
  • Figure 13.14 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Type of Therapy
  • Figure 13.15 Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035 (USD Billion)
  • Figure 13.16 Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035 (USD Billion)
  • Figure 13.17 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Route of Administration
  • Figure 13.18 Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035 (USD Billion)
  • Figure 13.19 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035 (USD Billion)
  • Figure 13.20 Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035 (USD Billion)
  • Figure 13.21 Berinert Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.22 EMPAVELI Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.23 ORLADEYO Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.24 Ruconest Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.25 Soliris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.26 Takhzyro Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.27 Ultomiris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.28 Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion)
  • Figure 13.29 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Target Disease Indication
  • Figure 13.30 Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035 (USD Billion)
  • Figure 13.31 Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035 (USD Billion)
  • Figure 13.32 Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035 (USD Billion)
  • Figure 13.33 Next Generation Complement Therapeutics Market for COVID-19, 2022-2035 (USD Billion)
  • Figure 13.34 Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035 (USD Billion)
  • Figure 13.35 Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035 (USD Billion)
  • Figure 13.36 Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035 (USD Billion)
  • Figure 13.37 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035 (USD Billion)
  • Figure 13.38 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Therapeutic Area
  • Figure 13.39 Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035 (USD Billion)
  • Figure 13.40 Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035 (USD Billion)
  • Figure 13.41 Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035 (USD Billion)
  • Figure 13.42 Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035 (USD Billion)
  • Figure 13.43 Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035 (USD Billion)
  • Figure 13.44 Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035 (USD Billion)
  • Figure 13.45 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Target Pathway
  • Figure 13.46 Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035 (USD Billion)
  • Figure 13.47 Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035 (USD Billion)
  • Figure 13.48 Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035 (USD Billion)
  • Figure 13.49 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Type of Therapy
  • Figure 13.50 Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035 (USD Billion)
  • Figure 13.51 Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035 (USD Billion)
  • Figure 13.52 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Route of Administration
  • Figure 13.53 Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035 (USD Billion)
  • Figure 13.54 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035 (USD Billion)
  • Figure 13.55 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Geography
  • Figure 13.56 Next Generation Complement Therapeutics Market in North America, 2022-2035 (USD Billion)
  • Figure 13.57 Next Generation Complement Therapeutics Market in US, 2022-2035 (USD Billion)
  • Figure 13.58 Next Generation Complement Therapeutics Market in Canada, 2022-2035 (USD Billion)
  • Figure 13.59 Next Generation Complement Therapeutics Market in Europe, 2022-2035 (USD Billion)
  • Figure 13.60 Next Generation Complement Therapeutics Market in UK, 2022-2035 (USD Billion)
  • Figure 13.61 Next Generation Complement Therapeutics Market in Germany, 2022-2035 (USD Billion)
  • Figure 13.62 Next Generation Complement Therapeutics Market in France, 2022-2035 (USD Billion)
  • Figure 13.63 Next Generation Complement Therapeutics Market in Italy, 2022-2035 (USD Billion)
  • Figure 13.64 Next Generation Complement Therapeutics Market in Spain, 2022-2035 (USD Billion)
  • Figure 13.65 Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035 (USD Billion)
  • Figure 13.66 Next Generation Complement Therapeutics Market in Australia, 2022-2035 (USD Billion)
  • Figure 13.67 Next Generation Complement Therapeutics Market in Japan, 2022-2035 (USD Billion)
  • Figure 13.68 Next Generation Complement Therapeutics Market in China, 2022-2035 (USD Billion)
  • Figure 13.69 Next Generation Complement Therapeutics Market in India, 2022-2035 (USD Billion)
  • Figure 13.70 Narsoplimab: Target Patient Population
  • Figure 13.71 Narsoplimab Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.72 REGN3918: Target Patient Population
  • Figure 13.73 REGN3918 Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.74 RG6107: Target Patient Population
  • Figure 13.75 RG6107 Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.76 rVA576: Target Patient Population
  • Figure 13.77 rVA576 Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.78 SAR445088: Target Patient Population
  • Figure 13.79 SAR445088 Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.80 Soliris: Target Patient Population
  • Figure 13.81 Soliris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.82 Sutimlimab: Target Patient Population
  • Figure 13.83 Sutimlimab Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.84 Vilobelimab: Target Patient Population
  • Figure 13.85 Vilobelimab Sales Forecast, 2022-2035 (USD Billion)
  • Figure 13.86 Zilucoplan: Target Patient Population
  • Figure 13.87 Zilucoplan Sales Forecast, 2022-2035 (USD Billion)

List Of Tables

  • Table 3.1 Sources of Key Complement Proteins
  • Table 3.2 Functions of Complement Proteins of Classical Pathway
  • Table 3.3 Diseases Related to Defects in Complement Proteins
  • Table 4.1 Next Generation Complement Therapeutics: Development Pipeline
  • Table 4.2 List of Drugs with Special Designations
  • Table 4.3 Next Generation Complement Therapeutics: List of Developers
  • Table 5.1 Amgen: Product Portfolio
  • Table 5.2 Recent Developments and Future Outlook
  • Table 5.3 CSL Behring: Product Portfolio
  • Table 5.4 Recent Developments and Future Outlook
  • Table 5.5 Innovent Biologics: Product Portfolio
  • Table 5.6 Recent Developments and Future Outlook
  • Table 5.7 Novartis: Product Portfolio
  • Table 5.8 Recent Developments and Future Outlook
  • Table 5.9 Regeneron: Product Portfolio
  • Table 5.10 Recent Developments and Future Outlook
  • Table 5.11 Roche: Product Portfolio
  • Table 5.12 Recent Developments and Future Outlook
  • Table 5.13 Sanofi: Product Portfolio
  • Table 5.14 Recent Developments and Future Outlook
  • Table 5.15 Takeda: Product Portfolio
  • Table 5.16 Recent Developments and Future Outlook
  • Table 5.17 UCB: Product Portfolio
  • Table 5.18 Recent Developments and Future Outlook
  • Table 6.1 Next Generation Complement Therapeutics: List of Clinical Trials, (till October 2021)
  • Table 7.1 Next Generation Complement Therapeutics: List of Publications, (till November 2021)
  • Table 9.1 Next Generation Complement Therapeutics: List of Patents, (till November 2021)
  • Table 10.1 Next Generation Complement Therapeutics: List of Partnerships and Collaborations, 2014-2021 (till November)
  • Table 11.1 Next Generation Complement Therapeutics: List of Funding and Investments (till November 2021)
  • Table 12.1 Big Pharma Players: Information on Revenues Generated in 2021
  • Table 13.1 Next Generation Complement Therapeutics: List of Forecasted Marketed Drugs
  • Table 13.2 Next Generation Complement Therapeutics: List of Forecasted Phase III Drugs
  • Table 13.3 Summary: Phase III Drugs

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. AbbVie
  • 2. Achillion Pharmaceuticals (acquired by Alexion Pharmaceuticals)
  • 3. Adage Capital Management
  • 4. ADIENNE
  • 5. Adverum Biotechnologies
  • 6. AffaMed Therapeutics
  • 7. AJU IB Investment
  • 8. Akari Therapeutics
  • 9. Alexion Pharmaceuticals
  • 10. Ally Bridge
  • 11. Alnylam Pharmaceuticals
  • 12. Alsonex
  • 13. Amgen
  • 14. Amyndas Pharmaceuticals
  • 15. Annexon Biosciences
  • 16. Apellis Pharmaceuticals
  • 17. Aquilo Capital
  • 18. argenx
  • 19. Assistance Publique - Hôpitaux de Paris (AP-HP)
  • 20. AstraZeneca
  • 21. Athyrium Capital Management
  • 22. Attune Pharmaceuticals
  • 23. Bain Capital Life Sciences
  • 24. Bayer
  • 25. Beam Therapeutics
  • 26. BioCryst Pharmaceuticals
  • 27. Biogen
  • 28. BioMarin Pharmaceutical
  • 29. Bioverativ (acquired by Sanofi)
  • 30. BlackRock
  • 31. Blackstone Life Sciences (BXLS)
  • 32. Boston University Medical Campus (BUMC)
  • 33. Boxer Capital
  • 34. Bristol Myers Squibb
  • 35. Broad Institute
  • 36. Broteio Pharma
  • 37. Burrage Capital Management
  • 38. Camurus
  • 39. CANbridge Pharmaceuticals
  • 40. Catalyst Biosciences
  • 41. Center for Research on Inflammatory Diseases (CRID)
  • 42. ChemoCentryx
  • 43. China Life Private Equity Investment
  • 44. Chugai Pharmaceutical
  • 45. Cincinnati Children's Hospital Medical Center
  • 46. Clarus (acquired by Blackstone)
  • 47. Clinigen
  • 48. Clough Capital Partners
  • 49. Columbia University Health Sciences
  • 50. Complement Pharma
  • 51. Cormorant Asset Management
  • 52. Correlation Ventures
  • 53. CRG Capital Partners
  • 54. CSL Behring
  • 55. CVie Therapeutics
  • 56. DAFNA Capital Management
  • 57. Deerfield Management
  • 58. Dicerna Pharmaceuticals
  • 59. Dompé Pharmaceuticals
  • 60. Duke University
  • 61. Dyax (acquired by Shire)
  • 62. East West Bank
  • 63. Epidarex Capital
  • 64. Eventide Asset Management
  • 65. Farallon Capital Management
  • 66. Federal Ministry of Education and Research (Germany)
  • 67. Federal Ministry of Health (Germany)
  • 68. Foresite Capital
  • 69. F-Prime Capital Partners
  • 70. Frazier Life Sciences
  • 71. Future Industry Investment Fund
  • 72. Genentech
  • 73. GENERIUM
  • 74. Genzyme (a subsidiary of Sanofi)
  • 75. GlaxoSmithKline
  • 76. Halozyme Therapeutics
  • 77. Harvard College
  • 78. Hemera Biosciences
  • 79. Hercules Capital
  • 80. Hillhouse Capital
  • 81. Icahn School of Medicine at Mount Sinai (ISMMS)
  • 82. I-Mab
  • 83. InflaRx
  • 84. Innate Pharma
  • 85. Innovent Biologics
  • 86. Ionis Pharmaceuticals
  • 87. IQVIA
  • 88. ISU ABXIS
  • 89. Iveric Bio
  • 90. Janus Henderson Investors
  • 91. Johns Hopkins University
  • 92. KalVista Pharmaceuticals
  • 93. Karolinska Institutet
  • 94. Kissei Pharmaceutical
  • 95. Legend Capital
  • 96. LifeSci Venture Partners
  • 97. Lilly Asia Ventures
  • 98. Logos Capital
  • 99. Longwood Fund
  • 100. Mallinckrodt
  • 101. Massachusetts General Hospital
  • 102. MidCap Financial
  • 103. Milestone Capital Advisors
  • 104. Morningside Ventures
  • 105. MorphoSys
  • 106. MPM Capital
  • 107. National Cancer Institute (NCI)
  • 108. National Institute of Allergy and Infectious Diseases (NIAID)
  • 109. National Institute of Mental Health (NIMH)
  • 110. National Institutes of Health Clinical Center (NIHCC)
  • 111. Neopharm
  • 112. New Enterprise Associates (NEA)
  • 113. NewBridge Pharmaceuticals
  • 114. Nichi-Iko Pharmaceutical
  • 115. Novartis
  • 116. Novartis Venture Fund
  • 117. NovelMed Therapeutics
  • 118. Novo
  • 119. NOXXON Pharma
  • 120. NYU Grossman School of Medicine
  • 121. Omeros
  • 122. OMERS
  • 123. OrbiMed Advisors
  • 124. Oxford Finance
  • 125. PANTHERx
  • 126. Parexel
  • 127. Paulson Investment
  • 128. Perceptive Advisors
  • 129. Pharmasyntez
  • 130. Pharming
  • 131. Ping An
  • 132. Prothix
  • 133. Qiming Venture Partners
  • 134. Quartesian
  • 135. QVT Financial
  • 136. RA Capital Management
  • 137. Ra Pharmaceuticals (acquired by UCB)
  • 138. Redmile
  • 139. Regeneron
  • 140. Regenesance
  • 141. Roche
  • 142. Rock Springs Capital
  • 143. Royalty Pharma
  • 144. RPC Pharma
  • 145. RTW Investments
  • 146. Samsung Bioepis
  • 147. Sanofi
  • 148. Satter Investment Management
  • 149. Satter Medical Technology Partners
  • 150. Sectoral Asset Management
  • 151. Selexis
  • 152. SFJ Pharmaceuticals
  • 153. Shire (acquired by Takeda)
  • 154. Silence Therapeutics
  • 155. Sobi
  • 156. Sofinnova
  • 157. Staidson Hongkong Investment
  • 158. Stanford University
  • 159. Surveyor Capital
  • 160. SV Life Sciences
  • 161. Taikang Insurance
  • 162. Takeda
  • 163. Tang Capital Management
  • 164. Tasly Biopharmaceuticals
  • 165. Temasek
  • 166. TF Capital
  • 167. Torii Pharmaceutical
  • 168. UCB
  • 169. UC San Diego
  • 170. University of California, San Francisco
  • 171. University of Cambridge
  • 172. University of Colorado
  • 173. University of Leicester
  • 174. University of Michigan
  • 175. University of North Carolina at Chapel Hill
  • 176. University of Pennsylvania
  • 177. University of Pittsburgh
  • 178. venBio Global Strategic Fund
  • 179. venBio Select
  • 180. Venrock
  • 181. Vifor Pharma
  • 182. Vivo Capital
  • 183. Washington University
  • 184. WuXi Biologics
  • 185. Xencor
  • 186. Yale University
  • 187. Zealand Pharma